Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DARING: Daclatasvir, Asunaprevir, and Ribavirin for HCV Genotype 1b
NCT03004625Phase 3Completed
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
- Start
- Nov 2016
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of daclatasvir and asunaprevir in hepatitis C (HCV), sponsored by Kaohsiung Medical University Chung-Ho Memorial Hospital. Primary endpoint: Sustained Virologic Response at 12 Weeks. Started Nov 2016; status: completed.
02
Drugs
daclatasvirasunaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03004625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03004625.